Characterization and in vitro antitumor activity of polysaccharides from the mycelium of Sarcodon aspratus
Characterization and in vitro antitumor activity of polysaccharides from the mycelium of Sarcodon aspratus
复制标题
Sarcodon aspratus 菌丝体多糖的表征及其体外抗肿瘤活性
DOI：
10.1016/j.ijbiomac.2012.09.005
复制
发表时间：
2013-01-01
影响因子：
8.2
通讯作者：
Guo, Wenqiang
中科院分区：
文献类型：
--
作者：
Chen, Yan;Hu, Meili;Guo, Wenqiang
从蘑菇中提取的多糖具有抗肿瘤、免疫刺激和降血糖等多种药用活性。本研究对沙棘多糖的性质及其抗肿瘤活性进行了研究，以期为其在医疗保健中的应用奠定基础。从Aspratus菌丝体中提取和分离出两个多糖组分(PSAN和PsaA)。PSAN和PSAA的平均分子质量分别约为5.6×10(4)Da和3.83×10(5)Da。PSAA由L鼠李糖、D-木糖、D-甘露糖组成，摩尔比为1：10：21；PSAA由L-鼠李糖、D-木糖、D-甘露糖、D-葡萄糖和D-半乳糖组成，摩尔比为1：39：76：10：21。PSAN和PSAA在体外对Hela细胞均表现出较高的抗肿瘤活性。在浓度为400 mg/L、作用时间为24 h时，对PSAN和PSAA的抑制率分别为65%和80%。与5-FU相比，PSAN和PSAA对人正常肝细胞株L-02的杀伤活性明显低于对Hela肿瘤细胞的杀伤活性。从食用菌中提取的多糖可能是开发新型低毒抗肿瘤药物的潜在候选者。(C)2012爱思唯尔B.V.保留所有权利。
Polysaccharides extracted from mushrooms have shown a variety of medical activities, such as antitumor, immunostimulatory and hypoglycemic activity. In this study, characteristics and the antitumor activities of Sarcodon aspratus polysaccharides were investigated for the possibility of application of S. aspratus in health care and medicine. Two polysaccharide fractions (PSAN and PSAA) were extracted and isolated from the mycelium of S. aspratus. The average molecular weight of PSAN and PSAA were approximately 5.6 x 10(4) Da and 3.83 x 10(5) Da, respectively. PSAN was composed of L-rhamnose, D-xylose and D-mannose, with molar ratios of 1:10:21; PSAA consisted of L-rhamnose, D-xylose, D-mannose, D-glucose and D-galactose, with molar ratios of 1:39:76:10:21. Both PSAN and PSAA presented high antitumor activity against Hela cells in vitro. At a concentration of 400 mg/L and an exposure time of 24 h, the inhibition rates for PSAN and PSAA were 65% and 80%, respectively. PSAN and PSAA exhibited significantly lower cytotoxicity against human normal liver cell line L-02 than Hela tumor cells in comparison with 5-Fu. Polysaccharide extracted from an edible mushroom S. aspratus may be a potential candidate for developing a novel low toxicity antitumor agent. (C) 2012 Elsevier B.V. All rights reserved.